

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-152 (Cancelled).

153. (New) A therapeutic method for preventing or treating a vascular indication in a mammal which indication is characterized by a decreased lumen diameter, comprising:

- a) selecting an agent for TGF-beta elevation;
- b) administering a cytostatic dose of the agent to the mammal so as to inhibit smooth muscle cell proliferation, inhibit lipid accumulation, increase plaque stability, or any combination thereof.

154. (New) A therapeutic method for preventing or treating a vascular indication in a mammal which indication is characterized by a decreased lumen diameter, comprising:

- a) determining an agent for TGF-beta elevation;
- b) selecting a cytostatic dose of the agent; and
- c) administering the dose to the mammal so as to inhibit smooth muscle cell proliferation, inhibit lipid accumulation, increase plaque stability, or any combination thereof.

155. (New) The method of claim 153 or 154 wherein the indication is a cardiovascular indication.

156. (New) The method of claim 153 or 154 wherein the agent has reduced estrogenic activity or DNA adduct formation relative to tamoxifen.

157. (New) The method of claim 153 or 154 wherein the administration is systemic.
158. (New) The method of claim 153 or 154 wherein the administration is local.
159. (New) The method of claim 153 or 154 wherein the agent is administered in a sustained release dosage form.
160. (New) The method of claim 153 or 154 wherein the agent directly or indirectly increases the level of active TGF-beta.
161. (New) The method of claim 153 or 154 wherein the agent is a TGF-beta production stimulator.
162. (New) The method of claim 153 or 154 wherein the agent is a TGF-beta activator.
163. (New) The method of claim 153 or 154 wherein the agent increases the production of TGF-beta mRNA.
164. (New) The method of claim 153 or 154 wherein the agent is administered via a stent.
165. (New) The method of claim 153 or 154 wherein the administration is oral.
166. (New) The method of claim 153 or 154 wherein the smooth muscle cell proliferation is associated with procedural vascular trauma.

167. (New) The method of claim 166 wherein the procedural vascular trauma is due to organ transplantation, vascular surgery, transcatheter vascular therapy, vascular grafting, placement of a shunt or placement of an intravascular stent.

168. (New) The method of claim 166 wherein the administration is before or after, or both before and after said procedure.

169. (New) A method, comprising:

- a) determining an agent for TGF-beta elevation; and
- b) identifying a cytostatic dose of the agent effective to prevent or treat a vascular indication in a mammal which indication is characterized by a decreased lumen diameter.

170. (New) The method of claim 169 wherein the agent directly or indirectly increases the level of active TGF-beta.

171. (New) The method of claim 169 wherein the agent is a TGF-beta production stimulator.

172. (New) The method of claim 169 wherein the agent is a TGF-beta activator.

173. (New) The method of claim 169 wherein the agent increases the production of TGF-beta mRNA.

PRELIMINARY AMENDMENT

Serial Number: Unknown

Filing Date: Filed Herewith

Title: PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN ANALOGUES

Page 6
Dkt: 295.009US4

Conclusion

Claims 1-152 have been cancelled and claims 153-173 have been added. The pending claims are 153-173. Applicant respectfully submits that the amendments herein be entered prior to the Examiner taking up the application. The Examiner is invited to telephone Applicant's attorney at (612) 373-6959 to facilitate prosecution of this application.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully Submitted,

DAVID J. GRAINGER ET AL.


By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date

December 5, 2003

By



Janet E. Embretson
Reg. No. 39,665

"Express Mail" mailing label number: EV332567201US

Date of Deposit: December 5, 2003

This paper or fee is being deposited on the date indicated above with the United States Postal Service pursuant to 37 CFR 1.10, and is addressed to The Commissioner for Patents, Mail Stop Patent Application, P.O. Box 1450, Alexandria, VA 22313-1450.